This press release contains forward-looking statements and information about future developments in the sector, and the legal and business conditions of DAIICHI SANKYO EUROPE GmbH. Such forward-looking statements are uncertain and are subject at all times to the risks of change, particularly to the usual risks faced by a global pharmaceutical company, including the impact of the prices for products and raw materials, medication safety, changes in exchange rates, government regulations, employee relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the company. All forward-looking statements contained in this release hold true as of the date of publication. They do not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements that are explicitly expressed or implied in these statements. DAIICHI SANKYO EUROPE GmbH assumes no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company.
MEDIA CONTACT: Medical: Joris Versteden, Vice Director Medical and Scientific Affairs, Phone +49(0)89-78-08-497, joris.versteden@daiichi-sankyo.eu; Communications: Dr. Michaela Paudler-Debus, Head of Product PR Europe, Phone +49(0)89-78-08-685, michaela.paudler-debus@daiichi-sankyo.eu
